diethyl 2,2'-(oxetane-3,3-diyl)diacetate | 1262769-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethyl 2,2'-(oxetane-3,3-diyl)diacetate
• 英文别名: (3-ethoxycarbonylmethyl-oxetan-3-yl)acetic acid ethyl ester；ethyl 2-[3-(2-ethoxy-2-oxoethyl)oxetan-3-yl]acetate
• CAS: 1262769-94-7
• 化学式: C₁₁H₁₈O₅
• 分子量: 230.261
• InChiKey: NTDTTXWHMNHYOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 2,2'-(oxetane-3,3-diyl)diacetate 在 lithium aluminium tetrahydride 、 草酰氯 、 四丁基碘化铵 、 sodium hydride 、 二甲基亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 mineral oil 为溶剂， 反应 25.42h， 生成 3-{2-[(4-methoxybenzyl)oxy]ethyl}oxetan-3-ylethanal
  参考文献：
  名称：

  Concise synthesis and characterization of novel seco-steroids bearing a spiro-oxetane instead of a metabolically labile C3-hydroxy group

  摘要：

  Two novel stereoisomeric analogues of 1,25-dihydroxyvitamin D-3 bearing a spiro-oxetane at the C3 position of the A-ring have been designed and synthesized in a convergent manner. The absolute configuration at the Cl position of the synthesized compounds was determined by the circular dichroism exciton chirality method using the corresponding C1-allylic benzoates. The replacement of the C3-hydroxy group with a spiro-oxetane provided an advantageous conformational preference for the parent seco-steroids, which would facilitate the formation of a stable receptor complex. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2014.05.060
• 作为产物：
  描述：

  diethyl 2-(3-(2-ethoxy-2-oxoethyl)oxetan-3-yl)malonate 在 水 、 sodium chloride 作用下， 以 二甲基亚砜 为溶剂， 生成 diethyl 2,2'-(oxetane-3,3-diyl)diacetate
  参考文献：
  名称：

  PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS

  摘要：

  提供了一类DNA-PK抑制剂，具体而言，是由公式（III）表示的化合物或其药学上可接受的盐，以及在制备DNA-PK抑制剂相关药物时的使用。

  公开号：

  EP4063371A1

文献信息

• 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
  申请人：Novartis AG

  公开号：US20200017461A1

  公开（公告）日：2020-01-16

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R x , X 1 , X 2 , and R 1 are as defined herein, and methods of making and using same.

  本公开提供了化合物Formula (I′)的一种： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体或互变异构体，其中R x 、X 1 、X 2 和R 1 如本文所定义，并提供了制备和使用该化合物的方法。
• [EN] NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PDE10
  申请人：AMGEN INC

  公开号：WO2011143365A1

  公开（公告）日：2011-11-17

  Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物：(I)，如规范中定义的，含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10治疗可治疗的疾病或疾病的方法，如肥胖症、亨廷顿病、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症等。
• UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS
  申请人：ALLEN Jennifer R.

  公开号：US20110306587A1

  公开（公告）日：2011-12-15

  Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物，如本说明书中所定义的，含有它们的组合物以及制备这种化合物的方法。本文还提供了治疗可通过抑制PDE10治疗的疾病或疾病的方法，例如肥胖症，亨廷顿病，非胰岛素依赖性糖尿病，精神分裂症，双相情感障碍，强迫症等。
• Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors
  申请人：Allen Jennifer R.

  公开号：US08957073B2

  公开（公告）日：2015-02-17

  Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  式(I)的不饱和氮杂环化合物：如规范所定义，含有它们的组合物以及制备这种化合物的过程。此外，本文还提供了治疗PDE10抑制剂可治疗的疾病或疾病的方法，例如肥胖症，亨廷顿病，非胰岛素依赖性糖尿病，精神分裂症，双相障碍，强迫症等。
• 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
  申请人：Novartis AG

  公开号：US11192877B2

  公开（公告）日：2021-12-07

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

  本公开提供了一种式(I′)化合物： 或其药学上可接受的盐、水合物、溶液、原药、立体异构体或同系物，其中 Rx、X1、X2 和 R1 如本文所定义，以及制造和使用它们的方法。